FC
EW icon

Fairscale Capital’s Edwards Lifesciences EW Stock Holding History

Fairscale Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26K Hold
36
– – ﹤0.01% 366
2026
Q1 		$2.88K Hold
36
– – ﹤0.01% 368
2025
Q4 		$3.07K Hold
36
– – ﹤0.01% 357
2025
Q3 		$2.8K Hold
36
– – ﹤0.01% 389
2025
Q2 		$2.85K Buy
+36
New +$2.69K ﹤0.01% 383

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Fairscale Capital's EW Position: Q2 2026 in Review

Fairscale Capital held its Edwards Lifesciences (EW) position steady in Q2 2026 at 36 shares worth $3.26K. The position accounts for ﹤0.01% of the portfolio, ranked #366.

Fairscale Capital first reported a position in EW in Q2 2025 and has held it in 5 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Fairscale Capital held 36 shares of Edwards Lifesciences worth $3.26K as of Q2 2026.
  • Fairscale Capital left its Edwards Lifesciences share count unchanged in Q2 2026.
  • Edwards Lifesciences made up ﹤0.01% of Fairscale Capital's portfolio in Q2 2026, its #366 holding.
  • Fairscale Capital first reported a position in Edwards Lifesciences in Q2 2025 and has held it in 5 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.